Refine by
880 results found
-
My Journey to Accepting My Dissociative Identity Disorder
Coming forward as a professional with lived experience of DID has given me the freedom to show others that they can embrace who they are and accept all parts of themselves. -
Becoming Who I was Before Schizophrenia — Or Should I?
Surviving schizophrenia, and making it to the other side, has given me a new and improved identity that I embrace. -
A Cultural Experience of Recovery
My healing process continues as I channel my past into my art and storytelling. -
FDA Approves Pill for Postpartum Depression
The U.S. Federal Drug Administration (FDA) has approved the first oral medication, Zurzuvae , for the treatment of postpartum depression (PPD). Onset of PPD can occur during the late stages of pregnancy or after childbirth. Previously, PDD medication was only available via IV injection from a health care provider. The effectiveness of Zurzuvae was tested against placebos in two distinct, randomized, double-blind studies for a period of 14 days. In both studies, patients taking Zurzuvae showed a more significant decrease in depressive symptoms at study conclusion, and four weeks after, compared to placebo groups. The approval goes a long way in improving accessibility of PPD treatment for the many individuals the condition affects each year. To learn more, read the news release from the FDA. -
Research Finds Mixed Results in Antidepressant Maintenance Treatment of Bipolar 1
Patients with bipolar disorder experience cyclic episodes of mania and depression which makes symptom management challenging. Common treatment practices include antidepressants and mood stabilizers or antipsychotics. An international clinical trial study of 177 patients with Bipolar I in remission from a depressive episode were randomly assigned to continue antidepressant use for 52 weeks or taper antidepressant use after six weeks and begin taking a placebo at eight weeks. Patients continuing antidepressant use were significantly less likely to experience a depressive episode (17%) compared to those taking a placebo (40%). However, 12% experienced a manic episode compared to 6% in the placebo group. Further research is needed to better understand the maintenance of manic and depressive episodes in patients with bipolar disorder. To learn more, read the article in the New England Journal of Medicine. -
Finding Mental Health Support After Leaving My Hasidic Community
This upbringing ultimately took a serious toll on my mental health and pushed me to search for a community of my own. -
We Don’t Feel Safe: Marginalization and Mental Health Challenges in the Queer Community
We all need those who stand firmly atop the social hierarchy to listen to us and then use their privilege to act up for the queer community. -
Advancing Equity in Mental Health Care for Black/African Ancestry Communities
We plan to carve out a new path of advocacy for Black/African Ancestry communities. -
APA Releases Findings From 2023 Work in America Survey
In April 2023, the American Psychological Association (APA) surveyed 2,500 American adults about mental health in the workplace. About 1 in 5 workers (19%) rated their workplace as being very or somewhat toxic. These workers were more than twice as likely to have fair or poor mental health (58%) than those who rated their workplace as healthy (21%). And while a majority of respondents are satisfied with the mental health support they receive from their employer, there are significant areas for improvement. Fewer than half of respondents (43%) reported that their employer provides health insurance with coverage for mental health and substance use disorders. To learn more, see the findings from the American Psychological Association.